ELSEVIER

Progress in Nuclear Magnetic Resonance Spectroscopy

PROGRESS IN NUCLEAR
MAGNETIC RESONANCE
SPECTROSCOPY

www.elsevier.nl/locate/pnmrs

Author Index, Volume 34

Bildsøe, H., 1
Buchanan, G.W., 327

Duckett, S.B., 71

van Eck, E.H.R., 159

Griesinger, C., 93

Jakobsen, H.J., 1
Johnson Jr., C.S., 203

Koehl, P., 257
Kristensen, J.H., 1

Nielsen, N.C., 1

Sattler, M., 93
Schleucher, J., 93
Sleight, C.J., 71
Smith, M.E., 159

Williams, S., 301

ELSEVIER

Progress in Nuclear Magnetic Resonance Spectroscopy

PROGRESS IN NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY

www.elsevier.nl/locate/pnmrs

Subject Index, Volume 34

^{27}Al cross-polarisation experiment, 185–6
MAS NMR
  central transitions, 173–4, 177-9
  magnetic fields, 167, 171
  satellite transitions, 165–6, 181–3
  pulse frequencies, 164–5
  static NMR, 169, 171, 172, 175
  triple/five quantum MQMAS 2D spectra comparison, 197
N-acetylaspartate, 303, 305
Acrylonitrile, p-H_2 addition, 75, 85
Adjoint
  Hamiltonian, 18, 20
  representation, 15, 17
Affinity NMR, complex identification, 213
Ag^+
  Crown ethers, 344
  molecular syringe, 331
Alanine
  α-carbon spectra, 214
  COSY-DOSY 3D, 248, 249–50
  DOSY 2D, 237, 240
  meningiomas, 310, 313
[Γ]-Alumina, off-resonance nutation spectra 191,
Alzheimer's disease, 313
Amino acids
  2D NMR, 321
  animals, 303–310, 321
  cerebral, 301–26
  humans, 310–14
Amplitudes
  1D NMR, 278–9
  multidimensional NMR, 279–80
Anion complexation, crown ethers, 343, 345–6, 356–7, 358, 359
Anti-convulsants, GABA, 306–7, 309
Apodization
  1D NMR, 259, 262
  multidimensional NMR, 279
AR . *see* Autoregressive
Arginine
  COSY-DOSY 3D, 248, 249–50
  DOSY 2D, 237, 240
ARMA . *see* Autoregressive-moving average process
Aromatic resonances assignment
  INEPT pulse sequences, 144
  PLUSH-TACSY pulse sequences, 142–4
  protein NMR, 141–4
Artifact suppression, pulsed field gradients, 94, 105–7
Aspartate, 302, 303, 305
Aspartate/glutamte modulation, 306
Asymmetry parameter effects, solid state NMR, 163–4
ATP/[Γ]-cyclodextrin
  PFG-DQS, 253
  PFG-TOCSY, 252–3
Autocorrelation methods, 263–4
Autoregressive (AR)
  coefficients, 263–4, 266–72
  processes, 262–274, 286–7
  time series, 262–3, 264–5
Autoregressive-moving average process (ARMA), 265–6, 291

^{11}B
  MAS NMR, borate glasses, 183
  NMR, crown ethers, 357–8
Backbone resonances assignment
  protein NMR, 113–146
  automated, 154
Backward linear prediction, 265, 289
Bi-polar (BPP) sequences, chemical shift encoding, 236, 239
Bi-polar LED sequences (BPP-LED), 214, 215–7, 232, 251
Bi-polar STE sequences (BPP-STE), 216–7
Binding ratios
  BSA-SDS equilibria, 244
  small/large molecules, 212
Binomial pulse methods, 315, 316, 319
Biofluids, DOSY 2D, 237, 239–40
Biomolecular NMR, 154
Bloch equations, PFG-NMR, 207–8
Bloch-Siegert phase (BSP) shifts, 102–5
  backbone resonances, protein NMR, 113, 114, 128
  TRAPDOR experiments, 190
Blood plasma
  lipoproteins, 243, 245–6
  PFG-STE-WATERGATE, 211, 212
Bovine serum albumin (BSA), -SDS equilibria, 240, 242–4
BPP . *see* Bi-polar
Brain
  cerebral amino acids, 301–26

PII: S0079-6565(00)00035-2

extracts, 238
in vivo spectra, 305, 320, 323
Breathing crown ethers, 336–7
BSA . *see* Bovine serum albumin
BSP . *see* Bloch-Siegert phase

^{13}C
cerebral amino acids
in vitro NMR, 307
in vivo NMR, 307–10, 312
CPMAS NMR, 359–68
large ring crown ethers, 367–8
small ring crown ethers, 363–7
HMQC-DOSY, 250–2
INEPT-DOSY/INEPT comparison, 220, 221, 225–6
^{13}C NMR
chemical shifts, complexation, 342–6
crown ether solutions, 340–349
iridium complexes, 77–79
lanthanide-induced shifts, 344–5
rhodium complexes, 86
solid crown ethers, 358–68
^{13}C-labeled protiens
modified pulse sequences, 143–6
multiple-quantum line narrowing, 111–113
$^{13}C/^{15}N$-edited NOESY experiments, 146–9
$^{13}C/^{15}N$-edited ROESY experiments, 149–150
$^{13}C/^{15}N$-labeled proteins
resonances, 94–100, 113–146
backbone, 113–146
side-chain, 129–146
Camphene, HMQC-DOSY, 252
Carbohydrate-deficient glycoprotein syndrome, 313, 318
Carr-Purcell spin-echo, 206, 209, 212
Cartan matrix, 22, 29
Cartan-Weyl operators, 3
Cartesian, 31–3
semi-simple Lie groups, 20–33
SU(2), 25–27
SU(3), 27–31
Cartesian SU(2) tensor operators, irreducible, 39–40, 46–7, 52
Casimir operators, 23, 27
Catenanes, supramolecular systems, 337–8
Cation complexation
^{1}H NMR, 328–334
^{13}C NMR, 341–2
CBCA(CO)NH experiments, 128–30
CBCANH experiments, 130–3
CBCANH/HNCACB experiments, sensitivity comparison, 133
Central transitions
MAS NMR, 171–80
principles, 160–3, 164
static experiments, 169
VAS NMR, 183
Cerebral amino acids, 301–26
Cerebral hypoxia, 302
Chemical exchange
DOSY applications, 234–9
FT-PFG NMR, 212
Chemical shift assignment
J-correlations, 96–100
NOE experiments, 94–100
Chemical shift encoding, 237–9
CHEmical Shift Selective (CHESS), water suppression, 315
Chemical shifts, ^{13}C NMR, 342–6
CHESS . *see* Chemical Shift Selective
Chiral recognition, crown compounds, 334
Choleski decomposition, 294
Circulant matrices, 293–5
^{35}Cl NMR, crown ethers, 358
Coherence transfer
experiments, 2–3
functions ^{2}H MAS NMR Hamiltonian, 17–20, 31–3, 53–62
functions integrated, 63–5
functions irreducible SU(2) tensor operaors, 39–45
heteronuclear NMR, 220
Coherence transfer pathway (CTP) selecion, 214–7
Compartmentation, cerebral amino acids, 307, 309
Complex identification, affinity NMR, 213
Complex radii, determination, 244
Complexation, data analysis, 342–3
Component resolved FT-PGSE NMR (CORE), Fortran programme, 233–4
Condition numbers, matrices, 269, 270, 295
Constant-time (CT), real-time, comparison, 116–119
CONTIN programme, DOSY analysis, 229, 230–2, 234, 245–6, 253
Continuous regularization, 271
Convection currents, DOSY NMR, 217–8, 252
Cooley-Tukey algorithm, 258
CORE . *see* Component resolved FT-PGSE NMR
Correction factors, MAS satellite transiions, 165–6
Correlated data sets, multivariate analysis, 233
Correlated spectroscopy (COSY)
crown ethers, 349
iridium complexes, 79–80
rhodium complexes, 78–9, 85
Cortical extract, 304
COSY . *see* Correlated spectroscopy
COSY-DOSY 3D NMR, 248, 249-50
Covariance method, linear predictions, 266
CP . *see* Cross-polarization
CPMAS . *see* Cross Polarization and Magic Angle Spinning
CPRE . *see* Component resolved FT-PGSE NMR
Cross Polarization and Magic Angle Spinning (CPMAS) spectra, 359–68
Cross relaxation, hydrogenations, 86
Cross-polarization (CP) NMR
multiple resonance, 185–6
spinlocking, 180
Crown ethers, 328–77

breathing, 336–7
12-crown-4 systems
^{31}P solid state NMR, 371
deuterated complexes, 369–70
sandwich complexes, 331
15-crown-5 systems, deuterated compexes, 370
18-crown-6 systems
^{1}H NMR, 328–330, 334
^{13}C CPMAS spectra, 359–63
^{19}F NMR, 356
^{31}P NMR, 371
^{133}Cs NMR, 371
^{195}Pt NMR, 354–7
deuterated complexes, 369
solid state NMR, 359–63
solutions NMR, 328–30, 334, 354–7
24-crown-6 systems, alkyl ammonium, 329
30-crown-i0 systems, diquat, 329–30
deuterated, 366, 369–70
dynamic '3C NMR, 346–50
membrane-insertable, 350, 351
Cryptands
^{1}H NMR, 328
^{7}Li NMR, 352–3
^{23}Na NMR, 349, 350
^{133}Cs NMR
crown ethers, 337, 347, 350–1
solid crown ethers, 371
CT . *see* Constant-time
CTP . *see* Coherence transfer pathway
Cyclam, ^{1}H NMR, 333–4

DANTE refocusing, 316, 319
DAS . *see* Dynamic angle spinning
Data analysis, complexation, 342–3
Data collection, DOSY NMR, 220–222
Data inversion
DOSY NMR, 222–234
FFT/ILT comparison, 220, 223
Data processing, 2D MQMAS NMR, 195–7
DECRA . *see* Direct Exponential Curve Resolution Algorithm
Dementia, 313
Density operator
algebra, 1–3, 45, 53
Lie algebra relations, 17–20
Deuterated crown ethers, 366, 369–70
Deuterated proteins, triple resonance experiments, 94, 99, 133, 143–6, 149
Deviation density operator, 18–20, 63–5
DVF . *see* Discrete Fourier Transform
Difference spectroscopy, 318–9
Differential Scanning Calorimetry (DSC), crown ethers, 370
Diffusion coefficients, 207
alanine, 237, 240
brain extracts, 238
CONTIN analysis, 230–2
discrete samples, 224–9
FT-PFG-NMR, 212
glutamine, 237, 240
glycol, 218
Laplace spectrum, 223
lysine, 237, 240
polymer additives, 241, 244
reference deconvolution, 219–20
stop-and-go spinner, 217, 218
Diffusion ordered spectroscopy (DOSY)
1D/2D, 213–234
2D, biofluids, 237, 239–40
3D, 249–253
CONTIN programme, 229, 230–2, 234, 245–6, 253
convection currents, 217–8, 252
data collection, 220–222
eddy currents, 213–216
requirements, 205–6, 213
reviews, 206–7
stray field, 222
Digital filtering, 315
Dipolar dephasing (DD) technique, crown ethers, 359
Diquat, crown ether complexes, 329–30, 331–2
Direct 2D linear prediction spectral analyis, 283–4
Direct Exponential Curve Resolution Algoithm (DECRA), 233, 234
Direct products, coupled nuclear spin sysems, 11, 13–15
DISCRETE, Fortran programme, DOSY analysis, 224, 226
Discrete Fourier Transform (DFT), 259, 260, 262, 274–5, 285
circulant matrices, 293–4
spectral analysis, 290
Discrete samples, diffusion, 224–229
DOR . *see* Double angle rotation
DOSY . *see* Diffusion ordered spectroscopy
Double angle rotation (DOR), 160, 183–5, 198
Double STE (DSTE) sequences, 216
DSC . *see* Differential Scanning Calorimery
DSTE . *see* Double STE
Dynamic ^{13}C NMR, crown ethers, 346–50
Dynamic angle spinning (DAS), 2D NMR, 191–3, 198

Echo experiments
protein NMR, 123, 126, 129, 139–40 *see also* Gradient echoes
Echo time, in vivo NMR, 3 17–8
Eddy currents
DOSY, 213–216
shielding coils, 214
Energy levels, quadrupole interactions, 162
Epilepsy, 312–3
Evolution times
deuterated protein NMR, 143
multidimensional heteronuclear NMR, 116–119
protein NMR, 123, 129–30, 132–3
Exchange effects, diffusion spectra, 234–7

Excitation, selective with p-H_2, 87–8
Expectation values, 4–5, 17
Experimental NMR
  1D experiments, 169, 85
  2D experiments, 190–199
  background principles, 163–9
  multiple resonance, 185–190
  solid state, 159–201
Extended Prony method, 279, 290, 291
  linear prediction, 274–6
Extrapolation, linear prediction, 286, 287–8

^{19}F NMR, crown ethers, 354–7
Fast techniques, linear prediction, 273–4
FID . *see* Free induction decay
Field sweep NMR, static ^{27}A1, 171, 175
Filtered NOE experiments, differential
  molecular labelling, 150–4
Fortran
  component resolved FT-PGSE NMR, 233–4
  DISCRETE, DOSY analysis, 224, 226
  DOSY3D, 249–50
  SPLMOD, DOSY analysis, 225, 226–9, 234
Forward linear prediction, 265
Fourier Transform (FT)
  analysis LP improved, 285–90
  FT-PFG-NMR experiment, 211–213
  mathematical model, 258–9, 260–1
  noise reduction, 269
Free crown ethers, ^{1}H NMR, 334–7
Free induction decay (FID)
  1D NMR, 219-20
  apodization, 284, 286, 287
  data points, 265
  noise, 268
  signal, 259, 260
  solids, 164, 165–6, 170
  truncation, 284, 286, 287
Frequency stepped NMR, static ^{91}Zr, 171, 174
Frequency/decay rates calculation
  polynomial rooting, 276–7
  state-space models, 277–8
FF-PFG NMR, chemical exchange, 212
Fullerenes, ^{13}C NMR, 363

GABA . *see* [Γ]-Amino butyrate
GCSTE . *see* Gradient compensated stimulated echo
GCSTESL . *see* Gradient compensated stimulated echo spin
  lock
Geraniol, HMQC-DOSY, 252
[Γ]-Amino butyrate (GABA), 303
  anti-convulsants, 306–7, 309
  epilepsy, 312–13
  quantification, 314, 323
  in vitro, 310
Glucose detection, 2D NMR, 321
Glutamate
  ^{1}H NMR visibility, 309, 312
  acute liver toxicity, 304–6, 307
  cerebral levels, 313
  COSY-DOSY 3D, 248, 249–50
  DOSY 2D, 237, 240
  metabolic rates, 307–10
  recycling, 309–10
  single scan methods, 319-20
  in vivo, 302, 305, 310–12, 314
Glutamine
  acute liver toxicity, 304–6, 307
  cerebral levels, 313
  hepatic encephalopathy, 311
  metabolic rates, 307–10
  in vivo detection, 302
Glycine, non-ketotic hyperglycinemia, 312
Gradient compensated stimulated echo (GCSTE) sequences,
  215, 217
Gradient compensated stimulated echo spin lock
  (GCSTESL) sequences, 215, 217
Gradient echoes
  multiple-quantum line narrowing, 111–113
  protein NMR, 123, 126, 129, 139–40
  pulsed field gradients, 105–7
  sensitivity enhancement, 107–9
  water-flip-back, 109–111

^{1}H
see also Proton
  NOE, crown ethers, 331–2, 336
  NOESY, free crown ethers, 335–6
^{1}H NMR
  amino acids in vivo, 301–26
  crown ether solutions, 328–39
  cyclam, 333–4
^{2}H MAS NMR, 3
  coherence transfer functions, 53–62
  Lie algebra applications, 51–68
  Liouville-von Neumann equation, 53–62
  optimum spectroscopy, 62–8
^{2}H NMR, crown ethers, 368–70
^{2}H-labeled proteins, modified pulse seuences, 143–6
Hahn echo, 206, 209
  see also Carr-Purcell spin echo
Hahn stimulated echo, 208, 209
Hamiltonian, 2–3
  ^{2}H MAS NMR, 51–62
  adjoint, 18, 20
  homogeneous interactions, 19, 55
  nuclear spin interactions, 45–51, 68
  Schrödinger equation, 4–5
  truncation, 50–1, 52
  Zeeman, 50–53
Hankel matrices, 267, 277–8, 295
HBHA(CO)NH 3D experiments, 128
H(C)CH-TOCSY 3D experiments, 137–41

Heating effects, DOSY, 216, 217, 252
Hepatic encephalopathy, 303–6, 311
HETCOR . *see* Heteronuclear XY correlation experiments
Heteroatom NMR, crown ethers, 354–8
Heteronuclear chemical shifts, 2D NMR, 78–9
Heteronuclear multiple bond correlation (HMBC), crown ethers, 348–9
Heteronuclear multiple quantum coheren' (HMQC), crown ethers, 349
Heteronuclear NMR, dispersion increase, 220
Heteronuclear XY correlation experiments (HETCOR), 197-9
^{199}Hg NMR, crown ethers, 353
(H)CCCO(N)H PLUSH-TACSY 3D experiments, 134–6
H(CC)(CO)NH PLUSH-TACSY 3D experiments, 137–8
(H)CC(CO)NH-TOCSY 3D experiments, 133–6
H(CC)(CO)NH-TOCSY 3D experiments, 136–7
High-resolution DOSY (HR-DOSY), 238, 240
Hilbert space
  basis vectors, 3
  linear operator, 3–5
  state vectors, 3–17, 20–35
Histidinaemia, 302, 306
HMBC . *see* Heteronuclear multiple bond correlation
HMQC . *see* Heteronuclear multiple quantum coherence
HMQC-DOSY, 249, 250–2
HNCA 3D experiments, 113–119
  with ^{2}H decoupling, 145–6
HNCACB 3D experiments
  out-and-back, 132–3
  water-flip-back, 131
HNCACB/CBCANH 3D experiments, sensitivity comparison, 133
HN(CA)CO 3D experiments, 123–5
HNCO 3D 3D experiments, 113–114, 117–9
HN(CO)CA 3D experiments, 119–123
H(N)COCA 3D experiments, 119–123
HN*COCA* 3D experiments, reduced dimensionality, 126–9
Homogeneous interaction, 19, 55
HR-DOSY . *see* High-resolution DOSY
Human brain spectra, in vivo, 305, 320, 323
Hybrid spectral analysis, 280
Hydrogen, spin isomers, 72–3
Hydrogenation
  initiation by photolysis, 86
  organic compounds, 75, 84–91
  regioselectivity, 90
  reversibility, 90–1
  stereoselectivity, 90
Hyperammonemia, 303–305, 311–12
Hypoglycaemia, 302, 303, 306
Hypoxia, 305, 308

IEP . *see* Iterative enhancement procedure
ILT . *see* Inverse Laplace transform
Image processing, linear prediction, 292
Imaging reagents, ^{19}F NMR, 356
In vivo
  ^{13}C NMR, 312, 313–4
  NMR, 259, 301–326
INEPT-DOSY/INEPT comparison, 220, 221, 225–6
Inositol, hepatic encephalopathy, 311
Interactions
  Hamiltonian, truncation, 50–1, 52
  inhomogeneous, 19
  quadrupole, 161–3
Intermolecular NOES, determination, 150–154
Intramolecular NOES, determination, 150–154
Inverse Laplace transform (ILT), FFT comparison, 220, 223
Iridium complexes, p-H_2, 75–81, 83–4, 89–90
Irreducible representations
  decomposition L[SU(2)], 40–2
  decomposition L[SU(3)], 31–3, 42–5
  fundamental, 22–4, 30, 32
Irreducible tensor operators
  Cartesian SU(2), 39–40, 46–7, 52
  development, 33–4
  representations, 34–6
  semi-simple Lie groups, 33–45
  SU(2), 36–8, 45–6
Ischaemia, 303, 304, 308
Isotropic shift, MQMAS spectra, 195–6
Itaconic acid, hydrogenation, 89, 91
Iterative enhancement procedure (IEP), preprocessing, 272

J filters, NOESY experiments, 150–4
J-correlations, chemical shifts assignment, 96–100
J-resolved spectroscopy, 317, 321
Jacobi identity, Lie algebra, 9

K^+ complexes, ^{13}C NMR, 360, 370
^{39}K NMR, crown ethers, 351–2
Kinetic probe, p-H_2, 89–90

^{139}La NMR, crown ethers, 353
Lactate detection
  2D NMR, 321
  rat brain, 319
Lanczos algorithm, 269
Lanthanide-induced shifts (LIS)
  ^{1}H NMR, 332–3
  ^{13}C NMR, 344–5
Large ring crown ethers, ^{13}C CPMAS NMR 367–8
Larmor frequency, 161–2, 171, 179, 185
Least-squares (LS), 290–1, 295
  linear, 266–8
  regularization, 269–71, 291
LED . *see* Longitudinal eddy current delay or Longitudinal encode-decode
Levenberg-Marquardt (LM) algorithm 221, 224–6, 234
Levinson-Durbin algorithm, Toeplitz matrices, 266
Li^+ complexes
  ^{13}C NMR, 361, 362, 363, 366, 367
  ^{19}F NMR, 357

^{7}Li NMR
crown ether solutions, 352–3
isomerization promotor, 353
selectivity crown ethers, 344, 347
solid crown ethers, 371–2
Lie algebra, 1–69
semi-simple, 9
similarity transformations, 16–17
Lie groups, 1–2, 6–69
adjoint representation, 15–17
irreducible representations, 11
semi-simple, Cartan-Weyl operators, 20–33
Linear operator, Hilbert space, 3–5
Linear prediction (LP), 259–293
coefficients, 290
complete spectral analysis, 290–2
covariance method, 266
direct 2D, 283–4
Fourier Transform complement, 285–90
model spectral processing, 323
quantitative analysis, 290–2
Liouville space, 15–18
Liouville state vectors, 3, 17–18
Liouville-von Neumann equation, 18–20
^{2}H MAS NMR Hamiltonian, 53–62
Lipoproteins, 243, 245–6
LIS . *see* Lanthanide-induced shifts
Localization, cerebral amino acids, 314–5
Localized orbital local origin (LORG) calculations, 364
Longitudinal eddy current delay (LED), 213, 215
Longitudinal encode-decode, (LED), 215
LORG . *see* Localized orbital local origin
LP . *see* Linear prediction
LS . *see* Least-squares

Magic angle spinning (MAS)
see also Multiple Quantum Magic Angle Spinning (MQMAS)
borate glasses, 183
correction factors, 165–6
cross polarization, 185
crown ethers, 371–2
quadrupolar nuclei, 163, 172–183
REAPDOR experiments, 188–90
REDOR experiments, 186–8
satellite transitions, 181–3
solid state NMR, 171–183
and spinlocking, 179–80
TEDOR experiments, 186-8
TRAPDOR experiments, 188–90
Magnetic field gradients
PFG-NMR, 207
spectral editing, 319–21
Magnetic fields, ^{27}Al MAS NMR, 167, 171
Magnetic resonance imaging (MRI), conrast agents, 333–4
Magnetization helices, PFG-NMR, 206–7
MAS . *see* Magic angle spinning
Materials characterisation
1D experiments, 169–85
2D experiments, 190–99
multiple resonance, 185–90
Maximum entropy
DOSY processing module, 231, 232, 234
regularization, 271
MCR . *see* Multivariate curve resolution
Mechanisms, catalysis, 88–91
Membrane-insertable crown ethers, 350, 351
Meningiomas, 310, 313
Merged DOSY
PFG-DQS, 251,253
PFG-TOCSY, 252, 253
Metabolic pathways, cerebral amino acids, 308
Metabolic rates, ^{13}C NMR, 313–4
Metal ion NMR, crown ethers solutions, 349–354
Metal-dihydrides
heteronuclear chemical shifts, 77–9
p-H_2, 75–81
Metal-trihydrides, iridium complexes 83–4
Mg^{2+} selectivity, crown ethers, 347
Mobility ordered NMR (MOSY), 205, 216
Model-based linear prediction, FT alternative 275–9
Molecular syringes, crown ethers, 331
Molecular weight distributions (MWD), DOSY applications, 247–9
MOSY . *see* Mobility ordered NMR
MQ . *see* Multiple quantum
MQMAS . *see* Multiple Quantum Magic Angle Spinning
MRI . *see* Magnetic resonance imaging
Multidimensional NMR
amplitude extraction, 279–80
hybrid spectral analysis, 280
linear prediction, 279–84
protein solutions, 93–158
sensitivity enhancement, 107–9
see also Sensitivity
Multiple quantum line narrowing, protein NMR, 111–113
Multiple Quantum Magic Angle Spinning (MQMAS)
2D NMR, 193–9
data processing, 195–7
evolution times, 193–5
pulse sequences, 194
RIACT(II), 194
split-t_1, 193–4
TPPI, 194–5
z-filter, 193–4
Multiple quantum (MO)
DOSY analysis, 253
single scan editing, 319–21
solid state NMR, 160, 193—9
Multiple resonance
cross polarization, 185–6

REAPDOR, 188–90
REDOR, 186–8
SEDOR, 186–8
solid state NMR, 160, 185–90
TEDOR, 186–8
TRAPDOR, 188–90
Multivariate analysis, data sets, 233
Multivariate curve resolution (MCR), 233, 234
MWD . *see* Molecular weight distributions

^{15}N NMR, cerebral amino acids, 305
^{15}N-labeled proteins
modified pulse sequences, 143–6
resonances assignment, 94–100
Structure Activity Relationship (SAR) by NMR, 95
Na^+
complexes, crown ethers, 347–8, 361, 366–7, 370
transport rates, crown ethers, 350
^{23}Na
MAS spectra
satellite transitions, 181
solids, 173, 174, 176–7, 179
NMR
crown ether solutions, 349–50
solid crown ethers, 371–2
^{23}Na-^{31}P 2D-HECTOR spectra
DAS incorporated, 198
MQMAS incorporated, 198–9
Near-drowning syndrome, 313
NMR visibility, glutamate, 309, 312
NOE . *see* Nuclear Overhauser effect
NOESY . *see* Nuclear Overhauser enhancement spectroscopy
NOESY-DOSY, 252
NlOESY-ROESY 3D/4D experiments, 146–154
Noise reduction, 268–72, 274
preprocessing, 271–2
Noise-free NMR, autoregressive time series, 264–5
Non-ketotic hyperglycinemia, 312
Nuclear interactions, 161–3
Nuclear Overhauser effect (NOE)
chemical shifts assignment, 94–6
crown ethers, 348
hydrogenations, 86
intra- and intermolecular determination, 150–4
kinetics, 89–90, 161–3
metal-dihydrides, 80–81
protein NMR, 146–154
automated assignment, 154
Nuclear Overhauser enhancement spectroscopy (NOESY)
^{13}C/^{15}N-edited, 146–9
LP analysis, 286, 288
supramolecular systems, 338
water-flip-back, 109–111
Nuclear spin Hamiltonian, 45–51, 68
Nuclear spin systems, classification, 14–15
Nutation NMR
solids, 160, 164, 190–1
spinlocking, 180
Nyquist theorem, 259
^{17}O
cross-polarisation experiment, I
DAS 2D spectra, 192
DOR NMR spectra, 183–5
MAS NMR, 183
triple quantum MQMAS 2D spectra, 196–7
Off-resonance nutation, 191
Oligomeric proteins, structure determination, 150–4
Organomercury, ^{19}F NMR, 356
Osmium complexes, p-H_2, 76, 82
Out-and-back
reduced dimensionality experiments, 126–7
transfer experiments, comparison, 116

^{31}P NMR
crown ether solutions, 357
iridium complexes, 77–8
rhodium complexes, 78–9
solid crown ethers. 370–1
^{31}P/^{27}Al TRAPDOR spectra, 189
Parahydrogen induced polarisation (PHIP), 74–5, 80–1, 83, 85–6, 89–90
Parahydrogen (p-H_2)
acrylonitrile, 75
applications, 71–91
AX spin system, 73–4
generation, 73
iridium complexes, 75–81
kinetic probe, 89–90
palladium complexes, 75, 85
platinum complexes, 76, 82, 85
rhodium complexes, 75–6, 78–9, 86
ruthenium complexes, 74–6
Parahydrogen and synthesis allow dramatically enhanced nuclear alignment (PASADENA), 74-5
Parameters, non-integer spin quadrupolar nuclei, NMR, 167
Paraquat, crown ethers, 331
PASADENA . *see* Parahydrogen and synthesis allow dramatically enhanced nulear alignment
Perdeuterated protein NMR, 149
PFG-NMR . *see* Pulsed magnetic field gradient-NMR
PFG-STE-WATERGATE, blood plasma, 211, 212
Phase shifts, Bloch-Siegert, 102–5
Phase-modulating pulse sequence, sensitivity enhancement, 107–9
Phenylacetylene, hydrogenation, 88, 91
Phenylketonuria, 302, 306, 311
PHIP . *see* Parahydrogen induced polarisation
Phospholipid vesicles, diffusion, 230, 243, 245
Phosphonates, crown ethers, 371, 372
Platinum complexes, p-H_2, 76, 82, 85
Polycrystalline samples, ^{2}H MAS NMR, 65–8
Polydisperse samples, diffusion, 229–232, 244–9, 252–3

Polymer additives, DOSY 2D applications, 241–2, 244
Polymers, DOSY 2D applications, 248–9
Polyrotaxanes, supramolecular systems, 338, 339
Power spectra, applied pulses, 164
Preprocessing, 291
  iterative enhancement procedure, 272
  noise reduction, 271–2, 274
PRESS localization, in vivo NMR, 315, 316, 318–9
Propagator
  adjoint, 18
  Schrodinger equation, 4–5
Propylene, decane, DOSY 3D, 351, 253
Protein
  ^{13}C-labeled
    multiple-quantum line narrowing, 111–113
    modified pulse sequences, 143–6
  ^{13}C/^{15} N-labeled, resonances, 94–100, 113–146
  deuterated, triple resonance experiments, 94, 99, 133, 143–6, 149
  ^{15}N-labeled
  modified pulse sequences, 143–6
  resonances assignment, 94–100
  Structure Activity Relationship (SAR) by NMR, 95
  oligomeric structure determination, 150–4
Protein NMR, 93–158
  backbone resonances assignment, 113–146
  3D/4D experiments, 98–100
    echo experiments, 123, 126, 129, 139–40
  selective pulses, 100–102
  sensitivity enhancement, 107–9
    see also Sensitivity
  typical pulse sequences, 97
Protein-sodium dodecylsulphate SDS equilibria, 242–4
Proton-observe carbon-edited (POCE) method, 307–8
Proton/proton distance restraints, NOE experiments, 146–154
^{195}Pt NMR, crown ethers, 354, 355
Pulse responses, ^{27}Al, 164–5
Pulse sequences
  INADEQUATE, 88
  INEPT, 77, 86–7
  NOE. 80-1
  protein NMR, 97, 100–113
  spectral editing, 316
Pulsed field gradients, artifact suppression, 94, 105–7
Pulsed magnetic field gradient-DOS, 253
Pulsed magnetic field gradient-NMR (PFG-NMR), 205–13
  -STE diffusion, 209–211
  background, 207–8
  Bloch equations, 207–8
  pulse sequences, 208–9
  spin-echo (SE) sequences, 206, 209
Pulsed magnetic field gradient-TOCSY, 252–3

QIS . *see* Quadnipole induced shift
Ouadrupole frequencies, ^{27}Al pulse responses, 164–5
Quadrupole induced shift (QIS), MQMAS spectra, 195, 197
Quadrupole interactions, 161–3
Quadrupole moments, 167–9
Ouadrupole nuclei
  ^{27}Al pulse responses, 164–5
  experimental NMR, 159–201
  properties, 168–9
Quantification, amino acids, 321–3
Quinine, HMQC-DOSY, 252

Radioimmunotherapy, crown ethers, 344
RDCON . *see* Reference deconvolution
Real-time (RT)
  constant-time evolution times, comparson, 116–119
  evolution time, 123, 137
REAPDOR . *see* Rotational-Echo Adiabatic Passage Double Resonance
REDOR . *see* Rotational Echo Double Resonance
Reduced dimensionality, triple resonance experiments, 125–9
Reference deconvolution (RDCON), FT-PFG NMR, 219-20
Reference standards, in vivo, 322
Regioselectivity, p-H_2, 90
Regression analysis, 263–4
Regularization
  least-squares approach, 269–71
  maximum entropy, 271
  Tikhonov technique, 270–1, 274
Relaxation times
  ^{13}C crown ethers, 340–2, 348
  ^{1}H crown ethers, 332, 339
  in vivo correction, 322
Resolution enhancement
  1D NMR, 218–220
  2D NMR, 249–253
Resonances assignment, ^{13}C/^{15}N-labeled proteins, 94–100, 113–146
Reversibility, p-H_2, 90–1
Rhodium complexes
  catalysts, 88–91
  dimers, 83–4
  p-H_2, 75–6, 78–9
Rhodniin
  HN(CO)CA 3D experiments, 199–113
  H(N)COCA 3D experiments, 119–123
  selective pulses, 100–101
RNA NMR, multiple-quantum line narrowing, 113
ROESY . *see* Rotating frame Overhauser effect spectroscopy
Rotating frame Overhauser effect spectroscopy (ROESY)
  ^{13}C/^{15}N-edited, 149–50
  crown ethers, 336
Rotational-Echo Adiabatic Passage Double Resonance (REAPDOR), 188–90
Rotational-Echo Double Resonance (REDOR), 186–8
Rotaxanes, supramolecular systems, 338–9
Ruthenium complexes, p-H_2, 74, 76

SAR . *see* Structure Activity Relationship
Satellite transitions, 160
  asymmetry parameter effects, 164
^{11}B MAS NMR, 183
  magic angle spinning (MAS), 165–6, 181–3
  static experiments, 169
Schiff base type, crown ethers, 340, 343
Schrödinger equation, state vectors, 4–5
SDS . *see* Sodium dodecylsulphate
SE . *see* Spin-echo
Secondary chemical shift, amino acids NMR, 100
SEDOR . *see* Spin-Echo Double Resonan
Selective excitation of polarisation using PASADENA (SEPP), 87-8
Selective pulses, protein NMR, 100–102
Semi-constant time evolution, 118, 130, 139–41
Semi-simple Lie algebras, 9
Semi-simple Lie groups
  Cartan- Weyl operators, 20–33
  irreducible tensor operators, 33–45
Sensitivity, 94, 99
  backbone resonances assignment, 113, 121–3, 125
  constant-time/real-time comparison, 116–8
  enhancement, 107–9
  multiple-quantum line narrowing, 111–12
  reduced dimensionality experiments, 126–9
SEPP . *see* Selective excitation of polarisation using PASADENA
Sequential LP spectral analysis, 281–3
Shared-time evolution, *see* Semi-constant time evolution
Shielding coils, eddy currents, 214
Short-echo time STEAM spectra, 305, 310, 315, 320–1
Side-chain resonances
  ^{13}C/^{15}N-labeled proteins, 129–146
  specific, 143
Single scan editing, multiple-quantum NMR, 319–21
Singular value decomposition (SVD), 267–8, 273, 290–1, 296
  alternatives, 269
  preprocessing, 272
Small ring crown ethers
  ^{13}C CPMAS NMR, 363-7
  Li complexation, 364–5
Sodium dodecylsulphate (SDS)-protein equilibria, 242–4
Solid state NMR, experimental, 159–201
Solubilization, DOSY 1D applications, 239, 240–1
Solution ^{1}H NMR, crown ethers, 328–339
Solvent suppression
  pulsed field gradients, 105–7
  water-flip-back, 109–111
Spatial reorientation, solid state NMR, 160, 183–5, 191–3
Special unitary Lie groups
  SU(2)
    Cartan-Weyl operators, 25–27
    irreducible tensor operators, 3, 36–45
  SU(3), Cartan-Weyl operators, 27–31
  SU(N), 6, 9, 11, 14–15, 19
Specific side-chain resonances, 143
Spectral analysis, using sequential prediction, 281–3
Spectral editing, 304, 307, 316, 318–321
  diffusion, 212–213
  GABA detection, 319, 321
  glutamate/glutamine detection, 304, 307
Spectral processing, 322–3
Speech recognition, linear prediction, 292
Spin isomers, hydrogen, 72–3
Spin-Echo Double Resonance (SEDOR), solids NMR, 186–8
Spin-echo (SE)
  Carr-Purcell, 206, 209, 212
  PFG-NMR, 206, 209
  static ^{27}A1 NMR, 170, 172
  in vivo NMR, 317–8
Spinlocking, 179–80
SPLMOD, DOSY analysis, 225, 226–9, 234
Stack plot display, FT-PFG-NMR, 210, 212
State-space models, 277–8, 290–1
Static NMR
  ^{27}Al, 169, 172
    field sweep spectra, 171, 175
  ^{91}spin-echo effect, 170, 172
    Zr, frequency stepped, 171, 174
  crown ethers, 371
  echo approach, 170–71
  materials characterisation, 169–71
  quadrupole interactions, 163, 169–171
STE . *see* Stimulated echo
Stejskal-Tanner attenuation factor, 209, 212
Stereoselectivity, p-H_2, 90
Sternheimer antishielding factor, 167–9
Stimulated echo (STE) pulse sequence, PFG-NMR, 209-211
Stop-and-go sample spinner, 217, 218, 240, 245
Stray field, DOSY NMR, 222
Structure Activity Relationship (SAR) by NMR, ^{15}N-labeled proteins, 95
Styrene, hydrogenation reversibility, 91
Supramolecular systems, crown ethers, 337–9
Surface coils, in vivo NMR, 314–5
SVD . *see* Singular value decomposition

Tantalum complexes, metal-trihydrides, 76, 83
Taurine, in vivo NMR, 303, 310
TCA . *see* Tricarboxylic acid
TEDOR . *see* Transferred-Echo Double Resonance
Telecommunications, linear prediction, 292
^{205}T1 NMR, crown ethers, 353–4
TLS . *see* Total least-squares
TOCSY-DOSY, 250, 251, 252–3
Toeplitz matrices, 264, 266–7, 293–4, 296
  fast techniques, 273
  processed, 272
Toroid cavities, DOSY analysis, 254
Torsional angles, crown ethers, 361, 364
Total least-squares (TLS), 272, 274, 278, 290–1, 295

Transfer, out-and-back experiments comparison, 116
Transfer amplitudes
  backbone resonances, protein NMR, 113–127
  backbone and side-chain resonances, protein NMR, 129–43
Transfer functions, Schrödinger equation, 4–5
Transfer of Populations by Double Resonance (TRAPDOR), 180, 188–90
Transferred-Echo Double Resonance, (TEDOR), quadrupole nuclei, 186–8
Transformation FFT/ILT comparison, 220, 223
Transition metal complexes, 75–84
  catalysts, 84–91
Transverse Relaxation-Optimized Spectrascopy (TROSY), protein NMR, 95
TRAPDOR . *see* Transfer of Populations by Double Resonance
Tricarboxylic acid (TCA) cycle, 308–9
Triple resonance pulse sequences, protein solutions, 97, 100–113
Triple resonance spectroscopy, protein solutions, 93–158
Two dimensional ^{1}H exchange (EXSY) spectra, 331, 333–4
Two dimensional NMR
  heteronuclear chemical shifts detection, 78–9
  p-H_2, 78–81

Unitary Lie groups U(N), 6
VACSY . *see* Variable angle correlation spectroscopy
Variable angle correlation spectroscopy (VACSY), 286
Variable angle spinning (VAS), solids NMR, 183
VAS . *see* Variable angle spinning
Viscoelastic mycellar system, DOSY applications, 246

Water suppression, cerebral amino acids, 314–7
Water-flip-back, protein solutions, 94, 109–111
Watergate pulse sequence
  filter, combination, 152–4
  water-flip-back, combination, 111
Weyl operators, 20–3, 25–34
Wilkinson's catalyst, hydrogenation, 88–9

Zeeman interactions, 161, 368
  Hamiltonian, 50–3
Zero-quantum coherences (ZQCs), 216–7
Zirconium phosphonate, crown ethers, 371, 372

ELSEVIER

Progress in Nuclear Magnetic Resonance Spectroscopy

PROGRESS IN NUCLEAR
MAGNETIC RESONANCE
SPECTROSCOPY

www.elsevier.nl/locate/pnmrs

Contents of Previous Volumes

Volume 29
Direct coupling of chromatographic separations to NMR spectroscopy
J. C. LINDON, J. K. NICHOLSON and I. D. WILSON
NMR investigation of RNA structure
G. VARANI, F. ABOUL-ELA and F. H.-T. ALLAIN
Determination of acidity functions and acid strengths by ^{13}C NMR
D. FĂRCAŞIU and A. GHENCIU
Bone marrow NMR in vivo
F. SCHICK
Ab initio calculations of the NMR chemical shift
A. C. DE DIOS

Volume 30
Intermolecular interactions characterized by nuclear Overhauser effects
H. MO, T. C. POCHAPSKY
NMR diffusion measurements to characterise membrane transport and solute binding
A. R. WALDECK, P. W. KUCHEL, A. J. LENNON, B. E. CHAPMAN
Stray field magnetic resonance imaging
P. J. MCDONALD
Radiofrequency field gradient experiments
D. CANET
NMR techniques employing selective radiofrequency pulses in combination with pulsed field gradients
S. BERGER
^{23}Na NMR methods for selective observation of sodium ions in ordered environments
R. KEMP-HARPER, S. P. BROWN, C. E. HUGHES, P. STYLES, S. WIMPERIS
Unravelling molecular structure and conformation—the modern role of coupling constants
W. A. THOMAS
Toroids in NMR spectroscopy
J. W. RATHKE, R. J. KLINGLER, R. E. GERALD II, K. W. KRAMARZ, K. WOELK
Book Review NMR Spectroscopy: Basic Principles, Concepts, and Applications in Chemistry, by H. Günther
– G. A. MORRIS

Volume 31
Radiofrequency microcoils in magnetic resonance
A. G. WEBB
Magnetic resonance imaging of plants
J. A. CHUDEK, G. HUNTER
Motional model analyses of protein and peptide dynamics using ^{13}C and ^{15}N NMR relaxation
V. A. DARAGAN, K. H. MAYO
Internet conferences in NMR spectroscopy
B. J. HARDY, S. W. DOUGHTY, M. F. PARRETTI, J. TENNISON, B. E. FINN, K. GARDNER
Nuclear magnetic resonance spectroscopy of molecules in the gas phase
C. B. LEMASTER
Quantitative localized ^{1}H MR spectroscopy for clinical use
R. KREIS
Reference deconvolution methods
G. A. MORRIS, H. BARJAT, T. J. HORNE
NMR studies of water bound to biological molecules
G. OTTING
Erratum to "^{23}Na NMR methods for selective observation of sodium ions in ordered environments"
R. KEMP-HARPER, S. P. BROWN, C. E. HUGHES, P. STYLES, S. WIMPERIS
Parahydrogen induced polarization
JOHANNES NATTERER, JOACHIM BARGON
Theory and calculation of nuclear shielding constants
H. FUKUI
Characterizing porous media with NMR methods
A. TED WATSON, C. T. PHILIP CHANG

Volume 32
Dipolar averaging in NMR spectroscopy: From polarization transfer to cross relaxation
R. Brüschweiler
Solid-state NMR investigations on the nature of hydrogen bonds
E. Brunner, U. Sternberg
Shaped radiofrequency pulses in high resolution NMR
R. Freeman
Ambiguous NOEs and automated NOE assignment
M. Nilges, S. I. O'Donoghue
Off-resonance nutation nuclear magnetic resonance spectroscopy of half-integer quadrupolar nuclei
A. P. M. Kentgens
Theories of chemical shift anisotropies in proteins and nucleic acids
D. Sitkoff, D. A. Case
Technical aspects of NMR spectroscopy with biological macromolecules and studies of hydration in solution
Gerhard Wider
NMR of large (> 25 kDa) proteins and protein complexes
Cheryl H. Arrowsmith, Yu-Sung Wu
The use of NMR methods for conformational studies of nucleic acids
S. S. Wijmenga, B. N. M. van Buuren

Volume 33
Pharmacokinetics using fluorine NMR in vivo
P. Bachert
Quadrupole NMR relaxation of the noble gases dissolved in simple liquids and solutions. A critical review of experimental data in the light of computer simulation results
M. Luhmer, J. Reisse
A generalized ***k***-space formalism for treating the spatial aspects of a variety of NMR experiments
A. Sodickson, D. G. Cory
NMR spectroscopy as a tool for structure-based drug design
B.J. Stockman
^{13}C NMR spectroscopy of monoterpenoids
M. J. P. Ferreira, V. P. Emerenciano, G. A. R. Linia, P. Romoff, P. A. T. Macari, G. V. Rodrigues
Protein NMR relaxation: theory, applications and outlook
M. W. F. Fischer, A. Majumdar, E. R. P. Zuiderweg
NMR imaging of materials
J. B. Miller

Volume 34
Application of Lie algebra to NMR spectroscopy
J. H. Kristensen, H. Bildsøe, H. J. Jakobsen, N. C. Nielsen
Applications of the parahydrogen phenomenon: A chemical perspective
S. B. Duckett, C. J. Sleigh
Heteronuclear multidimensional NMR experiments for the structure determination of proteins in solution employing pulsed field gradients
M. Sattler, J. Schleucher, C. Griesinger
Recent advances in experimental solid state NMR methodology for half-integer spin quadrupolar nuclei
M. E. Smith, E. H. R. van Eck
Diffusion ordered nuclear magnetic resonance spectroscopy: principles and applications
C. S. Johnson jr.
Linear prediction spectral analysis of NMR data
P. Koehl
Cerebral amino acids studied by nuclear magnetic resonance spectroscopy in vivo
S. Williams
Nuclear magnetic resonance studies of crown ethers
G. W. Buchanan